What is the recommended outpatient management for a patient with chronic heart failure with reduced ejection fraction?

Management of Heart Failure with Reduced Ejection Fraction in the Outpatient Setting

All patients with chronic HFrEF should be initiated on four foundational medication classes—ARNI/ACE inhibitor/ARB, beta-blocker, mineralocorticoid receptor antagonist, and SGLT2 inhibitor—with rapid titration to target doses within 6-12 weeks, as this "fantastic four" combination reduces mortality by at least 20% per drug class and prevents sudden cardiac death. 1

Core Pharmacological Therapy

First-Line Foundational Medications (The "Fantastic Four")

1. Renin-Angiotensin System Inhibition:

• Sacubitril/valsartan (ARNI) is preferred over ACE inhibitors as first-line therapy, starting at 24/26-49/51 mg twice daily and titrating to target dose of 97/103 mg twice daily 1
• If ARNI is not accessible, initiate ACE inhibitor (enalapril 2.5 mg twice daily, target 10-20 mg twice daily; or lisinopril 2.5-5 mg daily, target 20-40 mg daily) 1
• ARBs (valsartan 40 mg twice daily, target 160 mg twice daily) are reserved for patients intolerant to ACE inhibitors due to cough 1

2. Beta-Blockers (Evidence-Based Only):

• Use only carvedilol, metoprolol succinate, or bisoprolol—these three specifically reduce mortality 1
• Carvedilol: start 3.125 mg twice daily, target 25 mg twice daily (<85 kg) or 50 mg twice daily (≥85 kg) 1
• Metoprolol succinate: start 12.5-25 mg daily, target 200 mg daily 1
• Bisoprolol: start 1.25 mg daily, target 10 mg daily 1
• Initiate in all stable patients NYHA class II-IV unless contraindicated 1

3. Mineralocorticoid Receptor Antagonists:

• Spironolactone 12.5-25 mg daily, target 25-50 mg daily, or eplerenone 25 mg daily, target 50 mg daily 1
• Particularly beneficial in NYHA class III-IV for survival improvement 1
• Monitor potassium and creatinine after 5-7 days, then every 5-7 days until stable 1

4. SGLT2 Inhibitors:

• Dapagliflozin 10 mg daily or empagliflozin 10 mg daily 1
• This is the only medication class with Class 1A recommendation across all HF phenotypes (HFrEF, HFmrEF, HFpEF) 1, 2
• Initiate regardless of diabetes status 3, 4

Diuretics for Symptom Management

• Loop diuretics (furosemide, bumetanide) or thiazides for fluid overload, always combined with ACE inhibitor/ARNI 1
• If GFR <30 mL/min, avoid thiazides except synergistically with loop diuretics 1
• For insufficient response: increase diuretic dose, combine loop diuretics with thiazides, or administer loop diuretics twice daily 1
• In severe refractory cases, add metolazone with frequent creatinine and electrolyte monitoring 1

Initiation Strategy and Titration Protocol

ACE Inhibitor/ARNI Initiation Protocol

1. Review and reduce diuretics 24 hours before starting to avoid excessive diuresis 1
2. Consider evening dosing when supine to minimize hypotension, though evidence is limited 1
3. Start low dose and uptitrate to target doses proven in trials 1
4. Monitor blood pressure, renal function, and electrolytes 1-2 weeks after each dose increment, at 3 months, then every 6 months 1
5. Avoid potassium-sparing diuretics during initiation 1
6. Strictly avoid NSAIDs as they worsen HF symptoms and should be withdrawn 1
7. Stop treatment if renal function deteriorates substantially 1

Rapid Initiation Approach

The 2023 ESC guidelines now recommend rapid administration and prompt titration of all four foundational drugs after HF decompensation (Class IB recommendation) 2. Target achievement of therapeutic doses within 6-12 weeks of diagnosis 4, 5.

Secondary Therapies for Persistent Symptoms

Digoxin

• For atrial fibrillation with any degree of symptomatic HF: use to slow ventricular rate and improve symptoms 1
• For sinus rhythm with persistent symptoms despite ACE inhibitor/diuretic: improves clinical status 1
• Usual dose: 0.25-0.375 mg daily if normal creatinine; 0.125-0.25 mg daily in elderly 1
• Combination with beta-blocker superior to either alone 1
• Contraindications: bradycardia, second/third-degree AV block, sick sinus syndrome, hypokalemia, hypercalcemia 1

Hydralazine/Isosorbide Dinitrate

• Hydralazine 25 mg three times daily, target 75 mg three times daily 1
• Isosorbide dinitrate 20 mg three times daily, target 40 mg three times daily 1
• Consider in patients intolerant to ACE inhibitors/ARBs, though may be inferior for mortality 1

Ivabradine

• Start 2.5-5 mg twice daily, titrate to heart rate 50-60 bpm, maximum 7.5 mg twice daily 1
• Primarily reduces hospitalizations rather than mortality 1

Monitoring and Safety

Key Laboratory Monitoring

• Check potassium and creatinine 5-7 days after MRA initiation, then every 5-7 days until stable 1
• Monitor blood pressure, renal function, electrolytes 1-2 weeks after each RAAS inhibitor dose change 1
• Recheck at 3 months, then 6-monthly intervals 1

Managing Adverse Effects

Hyperkalemia:

• Consider patiromer or sodium zirconium cyclosilicate to enable continuation of spironolactone 1
• These potassium binders allow uptitration to target MRA doses 1

Hypotension:

• Reduce or temporarily hold diuretics 1
• Consider evening dosing of RAAS inhibitors 1

Worsening Renal Function:

• Stop ACE inhibitor/ARNI if substantial deterioration occurs 1

Medications to Avoid

Class 3: Harm

• Nondihydropyridine calcium channel blockers (diltiazem, verapamil) are contraindicated 1
• Class IC antiarrhythmics and dronedarone increase mortality risk 1
• Thiazolidinediones increase HF symptoms and hospitalizations 1
• DPP-4 inhibitors saxagliptin and alogliptin increase HF hospitalization in diabetics 1
• NSAIDs worsen symptoms and should be avoided or withdrawn 1

Class 3: No Benefit

• Dihydropyridine calcium channel blockers (amlodipine, felodipine) show no benefit 1
• Vitamins, nutritional supplements, hormonal therapy (except to correct specific deficiencies) 1

Lifestyle and Non-Pharmacological Management

Dietary Modifications

• Control sodium intake in severe HF 1
• Avoid excessive fluid intake in severe HF 1
• Avoid excessive alcohol 1

Exercise and Activity

• Daily physical and leisure activities encouraged in stable patients to prevent deconditioning 1
• Exercise training programs recommended for stable NYHA II-III 1
• Rest not encouraged in stable conditions 1

Patient Education

• Teach symptom recognition and when to seek care 1
• Emphasize daily self-weighing 1
• Explain rationale for treatments and importance of adherence 1
• Discuss prognosis openly 1

Special Considerations

Iron Deficiency

• Intravenous ferric carboxymaltose or ferric derisomaltose for HFrEF or HFmrEF patients with iron deficiency (Class IIa recommendation) 2
• Improves functional status and quality of life 4

Device Therapy Referral

• Refer to HF specialist for consideration of ICD or CRT if prolonged QRS duration or persistent advanced symptoms despite optimal medical therapy 1

Follow-Up Frequency

• More frequent follow-ups necessary after medication initiation or titration to assess tolerability 1
• Reassess symptoms, health status, and LV function after foundational therapy initiation 3
• Timely referral to HF specialist if persistent advanced symptoms or worsening HF 3